RA
MYGN icon

Royce & Associates’s Myriad Genetics MYGN Stock Holding History

Royce & Associates’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-605,000
Closed -$3.72M – 795
2025
Q4 		$3.72M Sell
605,000
-65,000
-10% -$471K 0.04% 511
2025
Q3 		$4.84M Buy
+670,000
New +$3.98M 0.05% 476
2020
Q3 		– Sell
-3,157
Closed -$36K – 1107
2020
Q2 		$36K Buy
3,157
+287
+10% +$4.08K ﹤0.01% 1065
2020
Q1 		$41K Buy
2,870
+796
+38% +$16.8K ﹤0.01% 1032
2019
Q4 		$56K Sell
2,074
-191,088
-99% -$5.26M ﹤0.01% 1026
2019
Q3 		$5.53M Buy
193,162
+15,664
+9% +$456K 0.05% 465
2019
Q2 		$4.93M Buy
177,498
+35,267
+25% +$996K 0.04% 492
2019
Q1 		$4.72M Buy
142,231
+131,246
+1,195% +$4M 0.04% 519
2018
Q4 		$319K Sell
10,985
-56,788
-84% -$2.04M ﹤0.01% 956
2018
Q3 		$3.12M Buy
67,773
+225
+0.3% +$10K 0.02% 716
2018
Q2 		$2.52M Buy
67,548
+116
+0.2% +$3.92K 0.02% 775
2018
Q1 		$1.99M Buy
67,432
+40,043
+146% +$1.35M 0.01% 856
2017
Q4 		$941K Buy
27,389
+34
+0.1% +$1.15K 0.01% 984
2017
Q3 		$990K Buy
+27,355
New +$780K 0.01% 967
2016
Q4 		– Sell
-90,369
Closed -$1.86M – 1096
2016
Q3 		$1.86M Sell
90,369
-847,129
-90% -$21.5M 0.01% 824
2016
Q2 		$28.7M Sell
937,498
-347,200
-27% -$12.1M 0.19% 156
2016
Q1 		$48.1M Sell
1,284,698
-130,200
-9% -$4.91M 0.3% 87
2015
Q4 		$61.1M Sell
1,414,898
-856,770
-38% -$36.2M 0.36% 64
2015
Q3 		$85.1M Sell
2,271,668
-551,535
-20% -$19.6M 0.45% 40
2015
Q2 		$96M Sell
2,823,203
-580,997
-17% -$19.8M 0.41% 53
2015
Q1 		$121M Sell
3,404,200
-1,680,363
-33% -$60.1M 0.46% 43
2014
Q4 		$173M Sell
5,084,563
-3,821,502
-43% -$136M 0.6% 22
2014
Q3 		$344M Sell
8,906,065
-393,413
-4% -$14.7M 1.16% 3
2014
Q2 		$362M Sell
9,299,478
-136,235
-1% -$5.07M 1.08% 3
2014
Q1 		$323M Sell
9,435,713
-1,407,362
-13% -$43.6M 0.95% 6
2013
Q4 		$227M Sell
10,843,075
-163,500
-1% -$4.14M 0.65% 17
2013
Q3 		$259M Buy
11,006,575
+262,180
+2% +$7.45M 0.77% 9
2013
Q2 		$289M Buy
+10,744,395
New +$311M 0.89% 9

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royce & Associates's MYGN Position: Q1 2026 in Review

Royce & Associates sold out of Myriad Genetics (MYGN) in Q1 2026, closing a stake of 605,000 shares — an estimated $3.72M sold.

Royce & Associates first reported a position in MYGN in Q2 2013 and held it in 28 quarters. The position peaked at $362M in Q2 2014. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Royce & Associates reported no remaining Myriad Genetics position as of Q1 2026 after selling out during the quarter.
  • Royce & Associates sold 605,000 Myriad Genetics shares in Q1 2026, an estimated $3.72M.
  • Royce & Associates first reported a position in Myriad Genetics in Q2 2013 and held it in 28 quarters.
  • Royce & Associates's Myriad Genetics position peaked at $362M in Q2 2014.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.